Edition:
India

Agile Therapeutics Inc (AGRX.OQ)

AGRX.OQ on NASDAQ Stock Exchange Global Market

2.73USD
20 Apr 2018
Change (% chg)

$-0.17 (-5.86%)
Prev Close
$2.90
Open
$2.90
Day's High
$2.90
Day's Low
$2.72
Volume
11,935
Avg. Vol
65,406
52-wk High
$5.59
52-wk Low
$1.93

Latest Key Developments (Source: Significant Developments)

Agile Therapeutics Reports Q4 Loss Per Share $0.18
Tuesday, 13 Mar 2018 

March 12 (Reuters) - Agile Therapeutics Inc ::AGILE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.18.Q4 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.AGILE THERAPEUTICS - BELIEVES CASH AND CASH EQUIVALENTS AS OF DEC 31, 2017, TO BE SUFFICIENT TO MEET ITS OPERATING REQUIREMENTS THROUGH END OF 2018.  Full Article

Perceptive Advisors Reports 9.9 Pct Passive Stake In Agile Therapeutics
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - Perceptive Advisors LLC::Perceptive Advisors LLC Reports A 9.9 Pct Passive Stake In Agile Therapeutics Inc <<>> As Of Dec 22, 2017 - SEC Filing.  Full Article

Agile Therapeutics Gets Response Letter From FDA For Pregnancy Prevention Drug Twirla
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Agile Therapeutics Inc ::AGILE THERAPEUTICS, INC. RECEIVES A COMPLETE RESPONSE LETTER FROM THE FDA FOR TWIRLA® (AG200-15) FOR THE PREVENTION OF PREGNANCY.AGILE THERAPEUTICS - CRL STATES THAT FDA HAS DETERMINED THAT IT CANNOT APPROVE NDA FOR TWIRLA ITS PRESENT FORM.AGILE THERAPEUTICS INC - CRL IDENTIFIES DEFICIENCIES RELATING TO QUALITY ADHESION TEST METHODS.AGILE THERAPEUTICS-FDA INDICATED APPLICABLE SECTIONS OF AMENDED NDA SUBMITTED BY CO COULD BE INCORPORATED WHEN RESPONDING TO DEFICIENCIES NOTED IN CRL.AGILE THERAPEUTICS - CRL ALSO NOTED THAT OBSERVATIONS IDENTIFIED DURING INSPECTION OF A FACILITY OF CORIUM INTERNATIONAL FOR TWIRLA NDA MUST BE RESOLVED.AGILE THERAPEUTICS INC - CRL DOES NOT IDENTIFY ANY SPECIFIC ISSUES RELATING TO SAFETY OF TWIRLA.AGILE THERAPEUTICS SAYS CRL RECOMMENDS THAT CO ASSESS IN VIVO ADHESION PROPERTIES DEMONSTRATED IN SECURE CLINICAL TRIAL.AGILE THERAPEUTICS - CRL "QUESTIONS" THE IN VIVO ADHESION PROPERTIES OF TWIRLA & THEIR POTENTIAL RELATIONSHIP TO SECURE PHASE 3 CLINICAL TRIAL RESULTS.AGILE THERAPEUTICS INC - "WE ARE EVALUATING THE FDA'S RESPONSE".  Full Article

Agile Therapeutics Q3 loss per share $0.22
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Agile Therapeutics Inc :Agile therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.22.Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Agile Therapeutics Inc - PDUFA goal date for Twirla is December 26, 2017​.Agile Therapeutics - ‍believes cash, cash equivalents as of sept. 30, will be sufficient to meet its operating requirements into Q2 of 2018​.  Full Article

Agile Therapeutics board appointed CEO Al Altomari as chairman of board
Friday, 7 Oct 2016 

Agile Therapeutics Inc : On October 5, 2016, board appointed Al Altomari, president and CEO, as chairman of board effective immediately - SEC filing Source: (http://bit.ly/2dOmS1B) Further company coverage: [AGRX.O] ((bangalore.newsroom@thomsonreuters.com;)).  Full Article

Agile Therapeutics enters into first amendment to loan, security agreement with Hercules Capital, other banks, other financial institutions
Saturday, 27 Aug 2016 

Agile Therapeutics Inc : Entered into first amendment to loan and security agreement with Hercules Capital, Inc, other banks,other financial institutions . First amendment extends interest-only payments until January 31, 2017 in connection with first tranche of $16.5 million of term loan .Amendment extends co's option to draw down second tranche of $8.5 million of term loan facility provided under loan agreement until Mar 31,2017.  Full Article

Agile Therapeutics reports Q2 loss per share $0.29
Tuesday, 9 Aug 2016 

Agile Therapeutics Inc : Agile Therapeutics reports second quarter 2016 financial results . Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S . Q2 loss per share $0.29 . Says as of june 30, 2016 $59.2 million of cash and cash equivalents compared to $34.4 million as of december 31, 2015 .Says cash and cash equivalents will be sufficient to meet its operating requirements through end of 2017.  Full Article

Agile Therapeutics reports Q1 loss per share $0.27
Tuesday, 10 May 2016 

Agile Therapeutics Inc : Cash expected to fund operations through end of 2017 . Agile therapeutics reports first quarter 2016 financial results . Q1 loss per share $0.27 .Q1 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Agile Therapeutics Reports Q4 Loss Per Share $0.18

* AGILE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS